Lack Of Year-End Conclusion To EU Trilogues Means More Timetable Shifts Likely
This article was originally published in Clinica
All official meetings between the European Commission, the Council of the EU and the European Parliament to discuss the medical device and IVD regulatory texts have stopped ahead of the end of the Luxembourg Presidency of the Council. There is a hiatus now before these negotiations start up again under the Dutch Presidency in the new year. But where does that leave the medtech sector? Amanda Maxwell briefly summarizes the position as the year draws to a close
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.